U.S. markets open in 6 hours
  • S&P Futures

    4,613.00
    -41.75 (-0.90%)
     
  • Dow Futures

    35,608.00
    -188.00 (-0.53%)
     
  • Nasdaq Futures

    15,342.00
    -253.75 (-1.63%)
     
  • Russell 2000 Futures

    2,139.10
    -18.60 (-0.86%)
     
  • Crude Oil

    85.28
    +1.46 (+1.74%)
     
  • Gold

    1,815.50
    -1.00 (-0.06%)
     
  • Silver

    22.99
    +0.07 (+0.31%)
     
  • EUR/USD

    1.1408
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.7720
    0.0000 (0.00%)
     
  • Vix

    21.27
    +0.96 (+4.73%)
     
  • GBP/USD

    1.3646
    -0.0000 (-0.00%)
     
  • USD/JPY

    114.7190
    +0.1390 (+0.12%)
     
  • BTC-USD

    41,876.91
    -785.79 (-1.84%)
     
  • CMC Crypto 200

    1,003.52
    -22.21 (-2.17%)
     
  • FTSE 100

    7,567.70
    -43.53 (-0.57%)
     
  • Nikkei 225

    28,257.25
    -76.27 (-0.27%)
     

Intercept to Announce Third Quarter 2021 Financial Results on November 3, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2021 financial results prior to market open on Wednesday, November 3, 2021. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.

The conference call will be available on the investor page of our website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free domestic) or (315) 625-6894 (international) passcode 6266006. Archived webcasts will be available on Intercept’s website for approximately two weeks.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.

CONTACT

For more information about Intercept, please contact:

Investor inquiries: investors@interceptpharma.com

Media inquiries: media@interceptpharma.com